TIDMPRTC
PureTech Health PLC
26 April 2021
26 April 2021
PureTech Health plc
PureTech Founded Entity Gelesis Appoints Procter & Gamble
Veteran Jane Wildman to Board of Directors
Ms. Wildman brings extensive experience in brand building and
marketing in the consumer health and wellness space, both at
established market leaders and start-ups
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the
"Company"), a clinical-stage biotherapeutics company dedicated to
discovering, developing and commercializing highly differentiated
medicines for devastating diseases, is pleased to note that its
Founded Entity, Gelesis, announced the appointment of marketing
executive Jane Wildman to its Board of Directors. Ms. Wildman has
extensive experience as a board member, president and chief
marketing officer across Fortune-25, mid-sized and start-up
companies. The appointment comes as Gelesis looks toward the broad
United States launch of its commercial product, Plenity(R), this
year.
As President and Board Member of Combe Incorporated, a
personal-care consumer products company, Ms. Wildman successfully
led the company to record sales and profit growth ahead of peers.
Prior to Combe, Ms. Wildman was a Partner and Consultant with The
Partnering Group, where clients included Fortune 50 companies like
Walmart, Procter & Gamble and Nestle.
Ms. Wildman spent over 25 years at Procter & Gamble, where
she worked in beauty, health, baby, feminine care and food, both in
the U.S. and internationally. She served as global Vice President
and led the global marketing organization for Pampers, P&G's
largest brand. She led the repositioning of a declining Pampers
brand and during her tenure, Pampers doubled from $4 to $8 billion
in sales with over half of the sales in international.
The full text of the announcement from Gelesis is as
follows:
Procter & Gamble Veteran Jane Wildman Joins Gelesis Board of
Directors
Ms. Wildman brings extensive experience in brand building and
marketing in the consumer health & wellness space, both at
established market leaders and digitally native startups
BOSTON, April 26, 2021 - Gelesis, a biotechnology company
advancing nature-inspired superabsorbent hydrogels to treat excess
weight and metabolic disorders, announced the appointment of
marketing executive Jane Wildman to its Board of Directors. Ms.
Wildman has extensive experience as a board member, president, and
chief marketing officer across Fortune-25, mid-sized, and start-up
companies. The appointment comes as Gelesis looks toward the broad
launch of its commercial product, Plenity(R), this year.
"We believe we can help fundamentally change how the world
addresses weight management. Jane has devoted her career to
building brands that solve consumer problems, and her marketing and
branding expertise will help us as we launch Plenity later this
year," said Yishai Zohar, CEO and Founder of Gelesis.
As president and board member of Combe Incorporated, a
personal-care consumer products company, Ms. Wildman successfully
led the company to record sales and profit growth ahead of peers.
Prior to Combe, Ms. Wildman was a partner and consultant with The
Partnering Group, where she specialized in corporate strategy,
omni-channel marketing, transforming the user experience, and
multi-cultural marketing. Clients included Fortune 50 and digital
start-ups, including Walmart, P&G, and Nestle. Ms. Wildman
spent over 25 years at Procter & Gamble, where she worked in
beauty, health, baby, feminine care, and food both in the U.S. and
internationally. She served as global Vice President and led the
global marketing organization for Pampers, P&G's largest brand.
She led the repositioning of a declining Pampers brand and during
her tenure, Pampers doubled from $4 to $8 billion in sales with
over half of the sales in international.
"Throughout my career I have worked on many deeply personal
brands, from feminine health and dandruff to baby care. I'm
passionate about changing the conversation to personal empowerment,
and that's exactly what drew me to Gelesis," said Jane. "With
Plenity, we have the unique opportunity to change the stigmatized
conversation around weight. When it comes to something as personal
as weight and body image, it's your choice and your journey, but
you deserve the right partner to help you feel supported and
empowered."
About Gelesis
Gelesis is a consumer centered biotechnology company advancing a
novel category of treatments for weight management and gut health
related chronic diseases. Our non-caloric superabsorbent hydrogels
are inspired by the composition and mechanical properties (e.g.
firmness) of raw vegetables. They are conveniently administered in
capsules to create a much larger volume of small, non-aggregating
hydrogel pieces, that become an integrated part of the meals, and
act locally in the digestive system.
Our portfolio includes Plenity, an FDA cleared product to aid in
weight management, as well as potential therapies in development
for Type 2 Diabetes, Non-alcoholic Fatty Liver Disease
(NAFLD)/Non-alcoholic Steatohepatitis (NASH), and Functional
Constipation.
For more information, visit gelesis.com , or connect with us on
Twitter @GelesisInc.
About Plenity(R)
Plenity is FDA-cleared to aid in weight management in adults
with excess weight or obesity, Body Mass Index (BMI) of 25 to 40
kg/m(2), when used in conjunction with diet and exercise. Plenity
is designed to help you feel full while eating less.
The capsules are taken 20-30 minutes before lunch and dinner
with 16 oz of water, acting locally in the GI tract to make you
feel fuller. Using a novel biomimetic approach, its structure and
properties were inspired by vegetables. Plenity is available now in
a limited release, with broad commercial availability later in
2021.
For more information, visit myplenity.com .
Important Safety Information
-- Patients who are pregnant or are allergic to cellulose,
citric acid, sodium stearyl fumarate, gelatin, or titanium dioxide
should not take Plenity.
-- To avoid impact on the absorption of medications:
o For all medications that should be taken with food, take them
after starting a meal.
o For all medications that should be taken without food (on an
empty stomach), continue taking on an empty stomach or as
recommended by your physician.
-- The overall incidence of side effects with Plenity was no
different than placebo. The most common side effects were diarrhea,
distended abdomen, infrequent bowel movements, and flatulence.
-- Contact a doctor right away if problems occur. If you have a
severe allergic reaction, severe stomach pain, or severe diarrhea,
stop using Plenity until you can speak to your doctor.
Rx Only. For the safe and proper use of Plenity or more
information, talk to a healthcare professional, read the Patient
Instructions for Use , or call 1-844-PLENITY.
About PureTech Health
PureTech is a clinical-stage biotherapeutics company dedicated
to discovering, developing and commercializing highly
differentiated medicines for devastating diseases, including
inflammatory, fibrotic and immunological conditions, intractable
cancers, lymphatic and gastrointestinal diseases and neurological
and neuropsychological disorders, among others. The Company has
created a broad and deep pipeline through the expertise of its
experienced research and development team and its extensive network
of scientists, clinicians and industry leaders. This pipeline,
which is being advanced both internally and through PureTech's
Founded Entities, is comprised of 26 products and product
candidates, including two that have received FDA clearance and
European marketing authorization, as of the date of PureTech's most
recently filed Annual Report on Form 20-F. All of the underlying
programs and platforms that resulted in this pipeline of product
candidates were initially identified or discovered and then
advanced by the PureTech team through key validation points based
on the Company's unique insights into the biology of the brain,
immune and gut, or BIG, systems and the interface between those
systems, referred to as the BIG Axis.
For more information, visit www.puretechhealth.com or connect
with us on Twitter @puretechh.
Cautionary Note Regarding Forward-Looking Statements
This press release contains statements that are or may be
forward-looking statements, including statements that relate to the
company's future prospects, developments, and strategies. The
forward-looking statements are based on current expectations and
are subject to known and unknown risks and uncertainties that could
cause actual results, performance and achievements to differ
materially from current expectations, including, but not limited
to, our expectations regarding the appointment of Jane Wildman to
the Board of Directors at Gelesis, and those risks and
uncertainties described in the risk factors included in the
regulatory filings for PureTech Health plc. These forward-looking
statements are based on assumptions regarding the present and
future business strategies of the company and the environment in
which it will operate in the future. Each forward-looking statement
speaks only as at the date of this press release. Except as
required by law and regulatory requirements, neither the company
nor any other party intends to update or revise these
forward-looking statements, whether as a result of new information,
future events or otherwise.
Contact:
Investors EU media
Allison Mead Talbot Ben Atwell, Rob Winder
+1 617 651 3156 +44 (0) 20 3727 1000
amt@puretechhealth.com ben.atwell@FTIconsulting.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAZZGZDZFKGMZZ
(END) Dow Jones Newswires
April 26, 2021 08:05 ET (12:05 GMT)
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jul 2023 to Jul 2024